| Document |
Document Title |
|
WO/2024/085725A1 |
The present invention pertains to a novel compound derivative and a pharmacological use thereof and specifically to a novel 1,1-dioxo-1,2-benzisothiazole derivative or novel 3-citryl-1H-pyrazole derivatives possessing antiplatelet activi...
|
|
WO/2024/072930A1 |
D3R selective partial agonists and their use in treating substance use disorders alone or in combination with affective disorders are disclosed. These substance use disorders include psychostimulant use disorder (PSUD). Compounds include...
|
|
WO/2024/059559A1 |
The invention provides isothiazolylcarboxamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or co...
|
|
WO/2024/046323A1 |
Provided are benzo five-membered nitrogen ring compounds, a preparation method therefor, and the medical uses thereof. Specifically provided are: benzo five-membered nitrogen ring compounds, or pharmaceutically acceptable salts, isomers,...
|
|
WO/2023/064363A9 |
The present disclosure relates to novel salts and salt forms of (2R)-2-(2-chlorophenyl)-2- (methylamino)cyclohexan-1-one (R-ketamine) and to processes for their preparation. The disclosure is also directed to pharmaceutical compositions ...
|
|
WO/2023/250140A1 |
Disclosed is a method for treating subarachnoid hemorrhage (SAH) and/or reducing the incidence of subsequent cerebral vasospasm in a patient. The method involves administering a therapeutically effective amount of a first compound or a p...
|
|
WO/2023/226964A1 |
The disclosure relates to heterocyclic derivatives as shown in Formula (I), to pharmaceutical compositions comprising them, to a process for their preparation, and their use as therapeutic agents.
|
|
WO/2023/208108A1 |
Disclosed herein is a compound for reducing uric acid, which is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof. The present invention can significantly reduce the serum uric acid level in a ra...
|
|
WO/2023/193809A1 |
Provided in the present disclosure are an SARM1 inhibitor compound of formula (I), a pharmaceutical composition containing same, and a preparation method therefor and the uses thereof. The compounds can be used for inhibiting SARM1 and/o...
|
|
WO/2023/192595A1 |
Disclosed herein are thiazolylphenol compounds 1 and methods of using the same for the treatment of subjects in need of a treatment for an infection by a microbe.
|
|
WO/2023/156398A1 |
The present invention relates to isothiazolo[3,4-b]pyridines of Formula (I), or an agronomically acceptable salt of said compounds wherein R1 and R2 are as defined herein. The invention further relates to herbicidal compositions which co...
|
|
WO/2023/118434A1 |
The present invention relates to novel pesticidally active amide compounds and in particular heteroaromatic amide compounds, to compositions comprising those compounds, and to their use in agriculture, for example in controlling insect p...
|
|
WO/2023/114818A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/114819A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/102162A1 |
Described herein are novel compounds, compositions and methods for treatment of diseases including cancer using such compounds, compositions, and methods. The compounds include those of Formula (I):
|
|
WO/2023/101595A1 |
The present invention is directed towards compounds of formula (I), capable of binding to sortilin and thereby useful as sortilin inhibitors in the treatment of diseases, disorders and conditions associated with sortilin activity and bin...
|
|
WO/2023/076626A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/032654A1 |
Provided is a method for selectively producing a high-purity 4-bromoisothiazolinone derivative at a good yield. Provided is a method for producing a 4-bromoisothiazolinone derivative represented by formula (1) (in which R is a hydrogen a...
|
|
WO/2023/025070A1 |
Provided are a thiazolecarboxamidine compound, and a preparation method therefor and the use thereof. The thiazolecarboxamidine compound is represented by the following general formula (I). The compound is a mitochondrial complex I inhib...
|
|
WO/2023/015395A1 |
Provided are beneficial and therapeutic Amanita muscaria compositions. In some embodiments, the provided /L muscaria compositions comprise A. muscaria extracts. In some embodiments, the provided A muscaria compositions comprise one or mo...
|
|
WO/2023/017703A1 |
Provided is an active-ray-sensitive or radiation-sensitive resin composition having excellent resolution properties and bridge margin, an active-ray-sensitive or radiation-sensitive film using said composition, a pattern formation method...
|
|
WO/2023/007188A1 |
The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, Formula (I), wherein, the group X-Y is -NHSO2-; Z is a monocyclic or polycyclic cycloalkyl group or a monocyclic or pol...
|
|
WO/2023/285788A1 |
A process for preparing a compound of formula (I), or a salt thereof, as defined herein. Also, compounds of formula I and intermediate compounds useful in the preparation of a compound of formula (I).
|
|
WO/2022/242462A1 |
Disclosed in the present invention are a benzoisothiazole hypoxia-inducible factor-2 (HIF-2) agonist compound or a pharmaceutically acceptable salt thereof. The compound can stimulate the HIF-2 transcriptional activity and enhance genera...
|
|
WO/2022/237780A1 |
An amide derivative and the pharmaceutical use thereof, in particular, the present invention relates to an amide derivative of formula (I) or a pharmaceutically acceptable salt thereof or all stereoisomers, tautomers and deuterated compo...
|
|
WO/2022/219246A1 |
The present invention relates to a compound of formula (I) wherein A, Z, L, R1, R2, R3, R4, R5 and R33 are as defined in claim 1, or a pharmaceutically acceptable salt thereof. The compounds of formula (I) possess utility as inhibitors o...
|
|
WO/2022/216627A1 |
Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such...
|
|
WO/2022/200347A1 |
The present application relates to a compound having the formula (I); A-L-B (I) wherein A is represented by; L is a bond or a self-immolative spacer; B is represented by; The compound is capable of releasing molecular cargo in the presen...
|
|
WO/2022/191312A1 |
[Abstract] [Problem] To provide a method for producing a dealkoxyphenylation product with high yield from a substrate, e.g., a sugar, which is bonded to an alkoxyphenyl group through an oxygen atom. [Solution] A substrate that is bonded ...
|
|
WO/2022/178283A1 |
Disclosed are compounds and methods for treating tauopathy.
|
|
WO/2022/174525A1 |
The present invention relates to the fields of medicinal chemistry and pharmacotherapeutics, and in particular to a compound, a preparation method therefor and a use thereof, relating to the technical field of pharmacy. Provided are a co...
|
|
WO/2022/174883A1 |
The present invention relates to a compounds of general formula (I) inhibiting both lysophosphatidic acid receptor 1 (LPA1) and receptor 2 (LPA2), particularly the invention relates to compounds that are 5-membered heterocyclyl derivativ...
|
|
WO/2022/133551A1 |
The present application is directed towards compounds, pharmaceutically acceptable salts or prodrugs thereof, which are inhibitors of Histone Deacetylase (HDAC) binding or function. The compounds especially may have some selectivity for ...
|
|
WO/2022/129047A2 |
The present invention is directed to novel modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorder...
|
|
WO/2022/129041A1 |
The present invention is directed to novel prodrugs of modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurologi...
|
|
WO/2022/122773A1 |
The present invention relates to 4-(2-Fluoro-4-methoxy-5-3-(((l- methylcyclobutyl)methyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)
carbamoyl)phenoxy)-l-methylcyclohexane-l-carboxylic acid derivatives and similar compounds of formula (I) as R...
|
|
WO/2022/116714A1 |
Provided in the present application are a compound and the medical use thereof for novel coronavirus pneumonia, which belongs to the technical field of pharmaceuticals. The compound is a compound represented by formula I or formula II, o...
|
|
WO/2022/103960A1 |
Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such...
|
|
WO/2022/091014A1 |
The present invention relates to an industrial method for the preparation of Benzisothiazolinone formula (I), which is simple, economical, efficient, user and environment friendly, moreover commercially viable with higher yield and chemi...
|
|
WO/2022/070451A1 |
Provided is a composition for treating water that has excellent storage stability as a liquid and high sterilization performance, a water treatment method in which the composition for treating water is used, a method for manufacturing th...
|
|
WO/2022/058965A1 |
Provided herein, inter alia, are compounds of fatty acid glycerol derivatives and compositions including the same.
|
|
WO/2022/051955A1 |
Disclosed is a method for preparing a saccharin compound. Provided is a method for preparing a saccharin compound as shown in formula (1). The method is characterized by comprising the following step: carrying out, in water in the presen...
|
|
WO/2022/008283A1 |
The present invention to a group of compounds of formula (I) useful for the transfer of polyfluoroalkylthiol groups of at least two carbons atoms into a great variety of organic compounds as well as to the process for their preparation. ...
|
|
WO/2020/102100A9 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2021/257849A1 |
Provided are compounds that can find use as nitrosation reagents. Provided are nitrosation methods that include reacting a substrate with one of the provided nitrosation reagents and thereby generating a nitrosation product. Provided are...
|
|
WO/2021/219089A1 |
Provided herein are compounds, pharmaceutical compositions and methods for treating a SARS-CoV-2 infection.
|
|
WO/2021/200178A1 |
The present invention provides: an actinic ray-sensitive or radiation-sensitive resin composition containing (A) a resin in which polarity is increased due to acid activity, and (B) a compound which is represented by a specific general f...
|
|
WO/2021/148934A1 |
The present invention relates to the process of reduction of compound of formula (II) by using a transition metal complex (Z) as a catalyst for hydrogenation reactions to get compound of formula (I). More particularly, the present invent...
|
|
WO/2021/115495A1 |
The present invention relates to a sulfur-containing heterocyclic compound, characterized by: a compound represented by the following structural formula (I) or stereoisomer thereof, a geometric isomer, a tautomer, a racemate, a deuterate...
|
|
WO/2021/083209A1 |
Provided are a compound of formula (I') or (I), a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of...
|
